• 1.
    • Working Group on Biomarker Definitions

    Biomarkers and surrogate criteria: preferred definitions and conceptual framework.

    Clin Pharmacol Ther. 2001; 69: 89-95

  • 2.
    • Sargent DJ
    • Goldberg RM
    • Jacobson DS
    • et al.

    A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients.

    N Engl J Med. 2001; 345: 1091-1097

  • 3.
    • Sargent DJ
    • Wieand HS
    • Haller CEO
    • et al.

    Disease-free survival versus overall survival as the primary endpoint of adjuvant colon cancer studies: individual data from 20,898 patients from 18 randomized trials.

    J Clin Oncol. 2005; 23: 8664-8670

  • 4.
    • Sargent D
    • ShiQ
    • The other G’s
    • et al.

    Two- or three-year disease-free survival (DFS) as primary endpoint in adjuvant stage III colon cancer trials of fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT , PETACC-3, C-06, C-07 and C89803.

    Eur J Cancer. 2011; 47: 990-996

  • 5.
    • Doorman G
    • Elias D
    • Mouth O
    • et al.

    Randomized multicentre trial of fluorouracil and folinic acid adjuvant compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial.

    J Clin Oncol. 2006; 24: 4976-4982

  • 6.
    • Hasegawa K
    • Saiura A
    • Takayama
    • et al.

    Uracil-tegafur oral adjuvant with leucovorin for colorectal cancer liver metastases: a randomized controlled trial.

    PLoS One. 2016; 11e0162400

  • seven.
    • Kanemitsu Y
    • Shimizu Y.
    • Mizusawa J.
    • et al.

    Hepatectomy followed by mFOLFOX6 versus hepatectomy alone for hepatic-only metastatic colorectal cancer (JCOG0603): a phase II or III randomized controlled trial.

    J Clin Oncol. 2021; 39: 3789-3799

  • 8.
    • Ychou M
    • Hohenberger W
    • Thezenas S
    • et al.

    A randomized phase III study comparing the adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients after complete resection of hepatic metastases from colorectal cancer.

    Anne Oncol. 2009; 20: 1964-1970

  • 9.
    • Araujo RLC
    • Hermann P.
    • Riechelmann RP

    Disease-free survival as a putative surrogate for overall survival in phase III trials of curative treatment of colorectal liver metastases: a systematic review.

    World J Clin Oncol. 2017; 8: 266-272

  • ten.
    • Kokudo T
    • Saiura A
    • Takayama
    • et al.

    Adjuvant chemotherapy may prolong disease-free survival but did not influence the type of disease recurrence or subsequent treatment in patients with colorectal liver metastases.

    Operation. 2021; 170: 1151-1154

  • 11.
    • by Gramont A.
    • Hubbard J.
    • ShiQ
    • et al.

    Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the ACCENT dataset of 20,800 patients.

    J Clin Oncol. 2010; 28: 460-465

  • 12.
    • Buisman FE
    • Homs MYV
    • Grünhagen DJ
    • et al.

    Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases – the PUMP multicenter randomized controlled trial.

    BMC Cancer. 2019; 19: 327

  • 13.

    Surrogate endpoints in clinical trials: definition and operational criteria.

    StatMed. 1989; 8: 431-440

  • 14.
    • Nordlinger B
    • Sorbye H
    • Glimelius B
    • et al.

    Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomized controlled trial.

    Lancet. 2008; 371: 1007-1016

  • 15.
    • Nordlinger B
    • Sorbye H
    • Glimelius B
    • et al.

    Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results from a randomized, controlled phase 3 trial.

    Lancet Oncol. 2013; 14: 1208-1215

  • 16.
    • GM page
    • McKenzie I
    • Bossuyt PM
    • et al.

    PRISMA 2020 reporting: an updated guideline for reporting systematic reviews.

    BMJ. 2021; 372: n71

  • 17.
    • Kemeny N.
    • Huang Y
    • Cohen AM
    • et al.

    Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer.

    N Engl J Med. 1999; 341: 2039-2048

  • 18.

    The I(2) heterogeneity statistic may be biased in small meta-analyses.

    Methodology BMC Med Res. 2015 ; 15: 35

  • 19.
    • Mound JM
    • Gonen M
    • Allen PJ
    • et al.

    Recurrence after partial hepatectomy for metastatic colorectal cancer: potentially curative role of salvage resection.

    Ann Surg Oncol. 2015 ; 22: 2761-2771

  • 20.
    • Tierney J.F.
    • Stewart LA
    • Ghersi D
    • Burdet S
    • Sydes MR

    Practical methods for incorporating summary time-to-event data into meta-analysis.

    Trials. 2007; 8: 16

  • 21.
    • MG House
    • Kemeny NE
    • Gonen M
    • et al.

    Comparison of adjuvant systemic chemotherapy with or without chemotherapy by hepatic arterial infusion after hepatic resection for metastatic colorectal cancer.

    Anne Surg. 2011; 254: 851-856

  • 22.
    • Kemeny MM
    • Adak S
    • Gray B
    • et al.

    Combined modality treatment of resectable metastatic colorectal carcinoma to the liver: surgical resection of liver metastases in combination with continuous infusion of chemotherapy – an intergroup study.

    J Clin Oncol. 2002; 20: 1499-1505

  • 23.
    • Mieras A
    • Pasman HRW
    • Klop HT
    • et al.

    What are the goals of patients and oncologists when starting medical treatment for metastatic lung cancer?.

    Lung cancer clink. 2021; 22: 242-251

  • 24.
    • Rand KL
    • Banno DA
    • Shea AM
    • Crip LD

    Life and treatment goals of patients with advanced and incurable cancer.

    Cancer Care Support. 2016; 24: 2953-2962

  • 25.
    • El-Jawahri A
    • Trager L
    • Park Emergencies
    • et al.

    Associations between prognostic understanding, quality of life and mood in patients with advanced cancer.

    Cancer. 2014 ; 120: 278-285

  • 26.
    • Buyse M
    • Molenbergh G
    • Pauletti X
    • et al.

    Statistical evaluation of surrogate endpoints with examples from cancer clinical trials.

    Biom J. 2016; 58: 104-132

  • 27.
    • Oba M
    • Hasegawa K
    • Matsuyama Y
    • et al.

    Difference between disease-free survival and overall survival in patients with resectable colorectal liver metastases: a potential surrogate endpoint for time to surgical failure.

    Ann Surg Oncol. 2014 ; 21: 1817-1824

  • 28.
    • Choti MA
    • JV Sitzmann
    • Tiburi MF
    • et al.

    Trends in long-term survival after hepatic resection for hepatic colorectal metastases.

    Anne Surg. 2002; 235: 759-766

  • 29.
    • Hoppener DJ
    • Nierop PMH
    • van Amerongen MJ
    • et al.

    The disease-free interval between resection of a primary colorectal malignancy and detection of liver metastases predicts disease recurrence but not overall survival.

    Ann Surg Oncol. 2019; 26: 2812-2820

  • 30.

    Five years of cancer drug approvals: innovation, efficacy and costs.

    JAMA Oncol. 2015 ; 1: 539-540

  • 31.
    • Miles DW
    • Chan A
    • Dirix LY
    • et al.

    Phase III study comparing bevacizumab and docetaxel with placebo and docetaxel for the first-line treatment of metastatic breast cancer at human epidermal growth factor receptor 2.

    J Clin Oncol. 2010; 28: 3239-3247

  • 32.
    • Robert NJ
    • Dieras V
    • Glaspy J
    • et al.

    RIBBON-1: randomized, double-blind, placebo-controlled trial of chemotherapy with or without bevacizumab (B) for the first-line treatment of locally recurrent or metastatic HER2-negative breast cancer (MSC).

    Proc Am Soc Clin Oncol. 2009; 27 1005

  • 33.
    • O’Shaughnessy J
    • Miles D
    • RJ gray
    • et al.

    A meta-analysis of overall survival data from three randomized trials of bevacizumab (BV) and first-line chemotherapy as treatment for patients with metastatic breast cancer (MSC).

    Proc Am Soc Clin Oncol. 2010; 28 1005

  • 34.
    • Carpenter D
    • Kesselheim AS
    • Joffe S

    Reputation and precedent in the bevacizumab decision.

    N Engl J Med. 2011; 365: e3

  • 35.
    • Takahashi S
    • Konishi M
    • Kinoshita T
    • et al.

    Predictors of early recurrence after hepatectomy for initially unresectable colorectal liver metastases.

    J Gastrointest Surg. 2013; 17: 939-948

  • 36.
    • Imai K
    • Allard MA
    • Benitez CC
    • et al.

    Early recurrence after hepatectomy for colorectal liver metastases: which optimal definition and which predictive factors?

    Oncologist. 2016; 21: 887-894

  • 37.
    • Kovic B
    • jinx holder
    • Kennedy SA
    • et al.

    Assessing progression-free survival as a surrogate outcome for health-related quality of life in oncology: a systematic review and quantitative analysis.

    Intern JAMA Med. 2018; 178: 1586-1596